Program as of August 19, 2008
| WEDNESDAY, JANUARY 21 |
KEYNOTE ADDRESS
7:30 p.m.-8:30 p.m.
Novel Approaches to Anti-Androgen Therapy
Charles L. Sawyers, Memorial Sloan-Kettering Cancer Center, New York, NY
|
OPENING RECEPTION
8:30 p.m.-10:00 p.m.
|
| THURSDAY, JANUARY 22 |
SESSION 1: ANIMAL MODELS
8:30 a.m.-10:00 a.m.
Targeting Differentiation Pathways for Pre-clinical Studies in Mouse Models of Prostate Cancer
Cory Abate-Shen, Herbert Irving Comprehensive Cancer Center at Columbia University, New York, NY
JOCK1: A Murine Model for FGFR1 Signaling in EMTs and PCa Progression
David M. Spencer, Baylor College of Medicine, Houston, TX
Title to be announced
Terry A. Van Dyke, National Cancer Institute, Frederick, MD
|
SESSION 2: PTEN
10:30 a.m.-12:00 p.m.
Title to be announced
Pier Paolo Pandolfi, Harvard Medical School, Boston, MA
PTEN and Hormone Refractory Prostate Cancer Development
Hong Wu, University of California, Los Angeles, CA
AKT-independent Signaling in the PI3 Kinase Pathway
Levi A. Garraway, Dana-Farber Cancer Institute, Boston, MA
|
SESSION 3: APOPTOSIS
2:00 p.m.-3:30 p.m.
Title to be announced
Xiodong Wang, UT Southwestern Medical Center, Dallas, TX
Apoptosis-based Therapies for Prostate Cancer
John C. Reed, Burnham Institute for Medical Research, La Jolla, CA
Do Fusion Genes Explain the Function of the Androgen Receptor in Prostate Cancer?
Jan Trapman, Erasmus University Medical Center, Josephine Nefkens Institute, Rotterdam, The Netherlands
|
FORUM ON BIOMARKERS BEYOND PSA
Presented by the National Cancer Institute's Early Detection Research Network (NCI-EDRN)
3:30 p.m.-5:00 p.m.
Moderators:
Sudhir Srivastava, National Cancer Institute, Rockville, MD and Arul M. Chinnaiyan, University of Michigan, Ann Arbor, MI
Discussants to be announced
|
POSTER SESSION A / DESSERT RECEPTION
7:30 p.m.-10:00 p.m.
|
| FRIDAY, JANUARY 23 |
SESSION 4: TECHNOLOGIES / IMAGING
8:30 a.m.-10:00 a.m.
Engineered Antibodies for Prostate Cancer Imaging
Anna M. Wu, David Geffen School of Medicine at UCLA, Los Angeles, CA
Toward Credentialing Circulating Tumor Cells and PET Imaging as Biomarkers in Castration Resistant Prostate Cancer
Howard I. Scher, Memorial Sloan-Kettering Cancer Center, New York, NY
Developing a Biophotonic Approach for Gene Transfer into Prostate Stem and Precursor Cells
Michael A. Teitell, David Geffen School of Medicine at UCLA, Los Angeles, CA
|
SESSION 5: TUMOR MICROENVIRONMENT
10:30 a.m.-12:00 p.m.
Regulation of Prostate Cancer Metastasis via Paracrine and Endocrine Signaling
Randolph S. Watnick, Harvard Medical School, Children's Hospital, Boston, MA
Regulation of Prostate Cancer Development
Owen N. Witte, University of California, Los Angeles, CA
Chemokines as Mediators of Prostate Tumorigenesis and Progression
Jill A. Macoska, University of Michigan, Ann Arbor, MI
|
POSTER SESSION B / LUNCH
12:00 p.m.-2:30 p.m.
|
SESSION 6: GENETIC SUSCEPTIBILITY / CANCER GENETICS
2:45 p.m.-4:45 p.m.
Interaction of Germline and Somatic Genetics in Prostate Cancer Progression
William B. Isaacs, Johns Hopkins Hospital, Baltimore, MD
Role of RNASEL/HPC1 in the Biology of Prostate Cancer
Robert H. Silverman, The Cleveland Clinic, Cleveland, OH
Title to be announced
John D. Carpten, Translational Genomics Research Institute, Phoenix, AZ
Germline Variants Associated with Prostate Cancer Risk
Jianfeng Xu, Wake Forest University School of Medicine, Winston-Salem, NC
|
| SATURDAY, JANUARY 24 |
SESSION 7: THERAPEUTICS / IMMUNOTHERAPY
8:30 a.m.-10:00 a.m.
Therapeutic Implications of Combinatorial Vascular Targeting in Prostate Cancer
Renata Pasqualini, UT M. D. Anderson Cancer Center, Houston, TX
Immune Checkpoint Blockade in Cancer Therapy
James P. Allison, Memorial Sloan-Kettering Cancer Center, New York, NY
Targeting CCL2 to Disrupt Cooperation Between the Host Cells of the Tumor Microenvironment and Prostate Cancer Cells
Kenneth J. Pienta, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI
|
SESSION 8: LATE-BREAKING RESEARCH
10:30 a.m.-12:30 p.m.
Role of the Tumor Microenvironment in Neoplastic Progression and Response to Therapy
Zena Werb, University of California, San Francisco, CA
Role of Polycomb Repressors in Cancer and Stem Cells
Maarten van Lohuizen, The Netherlands Cancer Institute, Amsterdam, The Netherlands
MicroRNAs in Prostate Cancer
Carlo M. Croce, Ohio State University Comprehensive Cancer Center, Columbus, OH
Recurrent Gene Fusions in Prostate Cancer
Arul M. Chinnaiyan, University of Michigan, Ann Arbor, MI
|
DEPARTURE |